BioCentury | Apr 12, 2010
Company News

Cytos, Independent Pharmaceutica, Nabi, Novartis, Celtic Pharma neurology news

...In an opposition brought by Nabi, Cytos, Novartis and Independent Pharmaceutica, the European Patent Office (EPO) revoked...
...plans. Nabi's NicVax nicotine conjugate vaccine is in Phase III testing to prevent nicotine dependence. Independent Pharmaceutica's...
...to treat nicotine addiction (see BioCentury, June 27, 2005). Cytos Biotechnology AG (SIX:CYTN), Zurich, Switzerland Independent Pharmaceutica AB...
BioCentury | May 5, 2008
Clinical News

Niccine: Phase II started

...company began a 1-year, double-blind, placebo-controlled, Scandinavian Phase II trial of Niccine in 400 patients. Independent Pharmaceutica AB...
Items per page:
1 - 2 of 2
BioCentury | Apr 12, 2010
Company News

Cytos, Independent Pharmaceutica, Nabi, Novartis, Celtic Pharma neurology news

...In an opposition brought by Nabi, Cytos, Novartis and Independent Pharmaceutica, the European Patent Office (EPO) revoked...
...plans. Nabi's NicVax nicotine conjugate vaccine is in Phase III testing to prevent nicotine dependence. Independent Pharmaceutica's...
...to treat nicotine addiction (see BioCentury, June 27, 2005). Cytos Biotechnology AG (SIX:CYTN), Zurich, Switzerland Independent Pharmaceutica AB...
BioCentury | May 5, 2008
Clinical News

Niccine: Phase II started

...company began a 1-year, double-blind, placebo-controlled, Scandinavian Phase II trial of Niccine in 400 patients. Independent Pharmaceutica AB...
Items per page:
1 - 2 of 2